Monoclonal Antibody Therapy of B-Cell Non-Hodgkin's Lymphoma
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.contributor.author | Dranitzki, Yuval | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
| dc.contributor.opponent | Drimba, László | |
| dc.contributor.opponent | Szentmiklósi, József András | |
| dc.contributor.opponentdept | Kenézy Kórház Aneszteziológiai és Intenziv Therápiás Osztály | hu_HU |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.date.accessioned | 2017-07-14T08:21:51Z | |
| dc.date.available | 2017-07-14T08:21:51Z | |
| dc.date.created | 2017-04-02 | |
| dc.description.abstract | Non-Hodgkin's lymphoma is the seventh most common cancer in the United States and the eleventh most common in Europe. It originates form lymphatic tissue with the most common source being B-cells. In the last 20 years a new type of therapy, monoclonal antibodies, has changed the way we treat NHL.In this review I will give the basics of non-Hodgkin's lymphoma and review the mechanisms of monoclonal antibody therapy, giving the most common examples of the current therapy. | hu_HU |
| dc.description.course | általános orvos | hu_HU |
| dc.description.courselang | angol | hu_HU |
| dc.description.degree | egységes, osztatlan | hu_HU |
| dc.format.extent | 38 | hu_HU |
| dc.identifier.uri | http://hdl.handle.net/2437/242580 | |
| dc.language.iso | en | hu_HU |
| dc.subject | Non-Hodgkin's | hu_HU |
| dc.subject | Lymphoma | hu_HU |
| dc.subject | Monoclonal | hu_HU |
| dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
| dc.title | Monoclonal Antibody Therapy of B-Cell Non-Hodgkin's Lymphoma | hu_HU |